1.
Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies
by Miossec, P
Annals of the Rheumatic Diseases, 2011-10, Vol.70 (10), p.1713-1718
2.
Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less
by Bélec, Laurent
Future microbiology, 2011-11, Vol.6 (11), p.1251-1260
3.
Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial
by de Jong, Evelien, Dr
The Lancet infectious diseases, 2016, Vol.16 (7), p.819-827
4.
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial
by Bouadma, Lila, MD
The Lancet (British edition), 2010, Vol.375 (9713), p.463-474
5.
Crohn's disease
by Torres, Joana, MD
The Lancet (British edition), 2016, Vol.389 (10080), p.1741-1755
6.
EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases
by Duru, N
Annals of the rheumatic diseases, 2013-12, Vol.72 (12), p.1905-1913
7.
New diagnostic tools in schistosomiasis
by Utzinger, J
Clinical microbiology and infection, 2015-06, Vol.21 (6), p.529-542
8.
Validation of a New Three-Item Self-Report Measure for Medication Adherence
by Wilson, Ira B
AIDS and behavior, 2016-04-20, Vol.20 (11), p.2700-2708
9.
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
by Costedoat-Chalumeau, Nathalie
Annals of the rheumatic diseases, 2013-11, Vol.72 (11), p.1786-1792
10.
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
by Peyrin-Biroulet, Laurent
Gut, 2014-01, Vol.63 (1), p.88-95
11.
Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns)
by Stocker, Martin
The Lancet (British edition), 2017-08-26, Vol.390 (10097), p.871-881
12.
Do Prescription Monitoring Programs Impact State Trends in Opioid Abuse/Misuse?
by Reifler, Liza M.
Pain medicine (Malden, Mass.), 2012-03, Vol.13 (3), p.434-442
13.
Prescription Drug Monitoring Programs and Death Rates from Drug Overdose
by Paulozzi, Leonard J.
Pain medicine (Malden, Mass.), 2011-05, Vol.12 (5), p.747-754
14.
Real-Time Adherence Monitoring for HIV Antiretroviral Therapy
by Haberer, Jessica E
AIDS and behavior, 2010-08-31, Vol.14 (6), p.1340-1346
15.
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
by Seow, C H
Gut, 2010-01, Vol.59 (1), p.49-54
16.
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strateg...
by Verstappen, S M M
Annals of the Rheumatic Diseases, 2007-11, Vol.66 (11), p.1443-1449
17.
Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice
by van der Goes, M C
Annals of the Rheumatic Diseases, 2010-11, Vol.69 (11), p.1913-1919
18.
Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial
by Wand, Ori
Chest, 2018-12, Vol.154 (6), p.1379-1384
19.
The future role of CD4 cell count for monitoring antiretroviral therapy
by Ford, Nathan, PhD
The Lancet infectious diseases, 2015, Vol.15 (2), p.241-247
20.
Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologis...
by Sivera, Francisca
Annals of the rheumatic diseases, 2014-02, Vol.73 (2), p.328-335
